Iconovo has recently entered into a strategic collaboration agreement with Lonza, one of the world’s leading CDMOs in the life sciences industry. The agreement aims to establish a long-term partnership between Iconovo and Lonza in spray-dried formulations, a technology that is central to the development of, among other things, inhaled biologics, vaccines, and other large molecules. Hear our CEO, Anders Månsson, explain more in the video.
Iconovo enters Strategic Collaboration with Global CDMO Leader Lonza
LinkedIn
Email
Related
Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report.
Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November.
The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved on a directed share issue of approximately SEK 25 million (the “Directed Issue”), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”, together the “Issues”).